AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28768141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-treated (enrofloxacin; Baytril® 100)
Number of subjects: 288
Study 28768141 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control
Number of subjects: 288
Study 26471159 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component brief intervention including clinician advice, video message, health education booklet, and follow-up coaching sessions.
Number of subjects: 334
Study 26471159 — intervention group
Group type: COMPARATOR
Intervention: Usual care and cancer screening information.
Number of subjects: 334
Study 24649762 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) as monotherapy, performed 1 time per week for 4 weeks.
Number of subjects: 30
Study 24649762 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (control group).
Number of subjects: 30
Study 21679343 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.5mg
Number of subjects: 42
Study 21679343 — intervention group
Group type: COMPARATOR
Intervention: Nocebo
Number of subjects: 42
Study 18758349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 383
Study 18758349 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant BMP-2 (rBMP-2)
Number of subjects: 383
Study 18758349 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant BMP-7 (rhBMP-7)
Number of subjects: 383
Study 18758349 — intervention group
Group type: COMPARATOR
Intervention: iliac crest bone graft (ICBG)
Number of subjects: 383
Study 17119724 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of pterygia and sampling of normal conjunctiva
Number of subjects: 36
Study 12787177 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0
Study 12787177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11052952 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with endurance training
Number of subjects: 16
Study 11052952 — intervention group
Group type: COMPARATOR
Intervention: endurance training alone (placebo group)
Number of subjects: 16
Study 8989735 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal NaCl diet (120 mmol/day)
Number of subjects: 43
Study 8989735 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol/day)
Number of subjects: 43
Study 8989735 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl intake (20 mmol/day)
Number of subjects: 43
Study 1299259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin treated with GC Conditioner for 10 seconds, rinsed with distilled water, dried with oil‐free compressed air, placement of GIC, sheared 7 days post‐curing
Number of subjects: 40
Study 1299259 — intervention group
Group type: COMPARATOR
Intervention: Dentin rinsed with distilled water, dried with oil‐free compressed air, placement of GIC, sheared 7 days post‐curing
Number of subjects: 40
Study 6329863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-fibre-rich diet (42.4 g dietary fibre/6.7 MJ)
Number of subjects: 14
Study 6329863 — intervention group
Group type: COMPARATOR
Intervention: Diabetic diet (18.9 g dietary fibre/6.7 MJ)
Number of subjects: 14
Study 31146540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 22
Study 31146540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30577871 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational program
Number of subjects: 5285
Study 30577871 — intervention group
Group type: COMPARATOR
Intervention: Usual routine
Number of subjects: 5285
Study 27327855 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-dose S-ketamine (0.015 mg/kg/h infusion following a saline bolus)
Number of subjects: 0
Study 27327855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine (0.25 mg/kg bolus and 0.125 mg/kg/h infusion for 48 hours)
Number of subjects: 0
Study 27327855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline bolus and infusion)
Number of subjects: 0
Study 25003802 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 3 (transportation plus prenatal/postpartum home visiting)
Number of subjects: 1138
Study 25003802 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 4 (transportation, screening, and prenatal, postpartum, and infant/toddler home visiting)
Number of subjects: 1138
Study 25003802 — intervention group
Group type: COMPARATOR
Intervention: Combined control group (treatments 1 and 2)
Number of subjects: 1138
Study 25003802 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 (transportation plus developmental screening for infants and toddlers)
Number of subjects: 1138
Study 22775763 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors management
Number of subjects: 4107
Study 22775763 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure management
Number of subjects: 4107
Study 22775763 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 4107
Study 22775763 — intervention group
Group type: COMPARATOR
Intervention: Lipid management
Number of subjects: 4107
Study 22775763 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agent use
Number of subjects: 4107
Study 19574331 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCOM programme (exercise training, education, nutritional therapy, smoking cessation counselling)
Number of subjects: 199
Study 19574331 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCOM programme
Number of subjects: 199
Study 19574331 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 199
Study 18797255 — intervention group
Group type: COMPARATOR
Intervention: Bottom-up attention condition with lateral blinking lights present
Number of subjects: 0
Study 18797255 — intervention group
Group type: COMPARATOR
Intervention: Top-down attention condition with imperative stimuli on the right side
Number of subjects: 0
Study 15615808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/day)
Number of subjects: 7
Study 15615808 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (60 mg/day)
Number of subjects: 7
Study 15615808 — intervention group
Group type: COMPARATOR
Intervention: Combination of furosemide and hydrochlorothiazide
Number of subjects: 7
Study 15615808 — intervention group
Group type: COMPARATOR
Intervention: Furosemide, hydrochlorothiazide, and their combination
Number of subjects: 7
Study 12878504 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 36
Study 12878504 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg
Number of subjects: 36
Study 12878504 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 500 mg
Number of subjects: 36
Study 9500717 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a, 3 MU three times a week for 6 months (n = 16)
Number of subjects: 31
Study 9500717 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 15)
Number of subjects: 31
Study 8562105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (46 patients: 5 mg/kg over 15 min and then 15 mg/kg over the subsequent 24 h for non-converting)
Number of subjects: 84
Study 8562105 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (38 patients: 2 mg/kg over 15 min and then 10 mg/kg over the subsequent 24 h for non-converting)
Number of subjects: 84
Study 8562105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 84
Study 8562105 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 84
Study 2237825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 18
Study 2237825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 18
Study 2237825 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18
Study 2237825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 602958 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sisomicin
Number of subjects: 120
Study 602958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion of sisomicin
Number of subjects: 120
Study 31842086 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection-based pay-for-performance (P4P) intervention
Number of subjects: 8423
Study 31842086 — intervention group
Group type: COMPARATOR
Intervention: Preintervention phase
Number of subjects: 8423
Study 28865339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole and early enteral nutrition
Number of subjects: 102
Study 28865339 — intervention group
Group type: COMPARATOR
Intervention: Placebo and early enteral nutrition
Number of subjects: 102
Study 27107029 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision contact lenses (one eye corrected for distance, the other for near vision)
Number of subjects: 13
Study 27107029 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous vision (progressive lenses)
Number of subjects: 13
Study 27107029 — intervention group
Group type: COMPARATOR
Intervention: Monovision
Number of subjects: 13
Study 27107029 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous vision
Number of subjects: 13
Study 28531467 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine consumption (once daily for 1 month)
Number of subjects: 40
Study 28531467 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (after a 1 month washout period)
Number of subjects: 40
Study 24158582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure PTFE-coated probes
Number of subjects: 10
Study 24158582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-reinforced PTFE-coated probes
Number of subjects: 10
Study 24158582 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel (control)
Number of subjects: 10
Study 20520568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost/timolol (Xalacom)
Number of subjects: 828
Study 18573123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical bone and bovine hydroxyapatite (HA) grafting on right sinuses
Number of subjects: 5
Study 18573123 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone plus bioglass (BG) material grafting on left sinuses
Number of subjects: 5
Study 17279183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone therapy
Number of subjects: 0
Study 14533368 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and walking protocol (12-week duration)
Number of subjects: 50
Study 14533368 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 11568690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (4000 IU)
Number of subjects: 100
Study 11568690 — intervention group
Group type: COMPARATOR
Intervention: Collagenase (400 ABC units)
Number of subjects: 100
Study 9776797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring tool with monthly feedback of phosphorus levels and interdialytic weight gains
Number of subjects: 40
Study 9776797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-monitoring tool)
Number of subjects: 40
Study 9776797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring tool
Number of subjects: 40
Study 7849688 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interventions consisting of visual, auditory, olfactory, gustatory and tactile stimulation
Number of subjects: 7
Study 3043077 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange with corticosteroids, cytotoxic drug, hemodialysis only when needed (Group I)
Number of subjects: 29
Study 3043077 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis with corticosteroids and cytotoxic drug (Group II)
Number of subjects: 29
Study 1396837 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 141
Study 1396837 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 141
Study 1396837 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 141
Study 1396837 — intervention group
Group type: COMPARATOR
Intervention: Overall (Amiodarone, Flecainide, Propafenone)
Number of subjects: 141
Study 363136 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol 50 microgram/day
Number of subjects: 49
Study 363136 — intervention group
Group type: EXPERIMENTAL
Intervention: norgestrel 250 microgram/day
Number of subjects: 49
Study 363136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiol (combination of ethinyl oestradiol and norgestrel)
Number of subjects: 49
Study 363136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 31931927 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyphthalide combined with idebenone
Number of subjects: 88
Study 31931927 — intervention group
Group type: COMPARATOR
Intervention: Idebenone
Number of subjects: 88
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not receive information about their medications
Number of subjects: 150
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not regularly visit a primary health-care provider
Number of subjects: 150
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who had changes in their treatment
Number of subjects: 150
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who reported using pillboxes
Number of subjects: 150
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who had help from a caregiver
Number of subjects: 150
Study 30241872 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who integrated medication dosing into daily routines
Number of subjects: 150
Study 28619692 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Options to Prevent Pregnancy intervention
Number of subjects: 598
Study 28619692 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 598
Study 27231800 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation (intervention group)
Number of subjects: 147
Study 27231800 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 147
Study 25093754 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin‐piperaquine (DP)
Number of subjects: 393
Study 25093754 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily trimethoprim‐sulfamethoxazole (TS)
Number of subjects: 393
Study 25093754 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine‐pyrimethamine (SP)
Number of subjects: 393
Study 25093754 — intervention group
Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 393
Study 22502956 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1195
Study 22502956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 1195
Study 22502956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive smoking
Number of subjects: 1195
Study 19068274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent FOLFIRI chemotherapy
Number of subjects: 266
Study 19068274 — intervention group
Group type: COMPARATOR
Intervention: Continuous FOLFIRI chemotherapy
Number of subjects: 266
Study 17321427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with parental support
Number of subjects: 15
Study 17321427 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 15362330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive skills training with fewer task repetitions (3 or 4)
Number of subjects: 21
Study 15362330 — intervention group
Group type: COMPARATOR
Intervention: Technical skills training with more task repetitions (5 or 6)
Number of subjects: 21
Study 12213435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium for at least 12 months
Number of subjects: 17
Study 9835004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (mean 5.2 x 10(6) KIU)
Number of subjects: 35
Study 9835004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU)
Number of subjects: 35
Study 9835004 — intervention group
Group type: COMPARATOR
Intervention: Control group without aprotinin
Number of subjects: 35
Study 9835004 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (including both aprotinin doses)
Number of subjects: 35
Study 9835004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin-treated patients (both doses)
Number of subjects: 35
Study 7730602 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern Balinese Baris Dancing Exercise (MBBDE)
Number of subjects: 60
Study 7730602 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 2521409 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoclone OKT3 for 14 days, azathioprine, and steroids
Number of subjects: 52
Study 2521409 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine, and steroids
Number of subjects: 52
Study 2521409 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoclone OKT3 for 14 days
Number of subjects: 52
Study 2521409 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoclone OKT3
Number of subjects: 52
Study 2521409 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 52
Study 2521409 — intervention group
Group type: COMPARATOR
Intervention: Orthoclone OKT3 and Cyclosporine
Number of subjects: 52
Study 1080382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone-prednisone combination
Number of subjects: 4
Study 1080382 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 4
Study 31172175 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal/kg of body weight/wk
Number of subjects: 198
Study 31172175 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kcal/kg of body weight/wk
Number of subjects: 198
Study 31172175 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 198
Study 29911777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Tretinoin Cream
Number of subjects: 48
Study 29911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Extract Cream
Number of subjects: 48
Study 25785703 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Carbohydrate (CHO) solution (15 g; 0.20 ± 0.02 g·kg(‐1))
Number of subjects: 15
Study 25785703 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Caffeine (CAF) solution (300 mg; 3.9 ± 0.3 mg·kg(‐1))
Number of subjects: 15
Study 25785703 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with caffeine (C + C) solution
Number of subjects: 15
Study 25785703 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo; PLA)
Number of subjects: 15
Study 25785703 — intervention group
Group type: COMPARATOR
Intervention: Control (no solution rinsed)
Number of subjects: 15
Study 25785703 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 15
Study 23480456 — intervention group
Group type: COMPARATOR
Intervention: M (PCA regimen with morphine)
Number of subjects: 94
Study 23480456 — intervention group
Group type: EXPERIMENTAL
Intervention: TM (PCA regimen with tenoxicam and morphine)
Number of subjects: 94
Study 23480456 — intervention group
Group type: EXPERIMENTAL
Intervention: T+TM (20 mg tenoxicam administered 30 minutes before wound closure in addition to the TM regimen)
Number of subjects: 94
Study 21619984 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I measurements at various time points (T6, T12, T24, T48, T72) and cumulative area under the curve (CAUC24, CAUC48, CAUC72)
Number of subjects: 440
Study 19334078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic block (LSB) with bupivacaine and botulinum toxin A (BTA)
Number of subjects: 9
Study 19334078 — intervention group
Group type: COMPARATOR
Intervention: Standard lumbar sympathetic block (LSB) with bupivacaine
Number of subjects: 9
Study 16633144 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 394
Study 16633144 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 394
Study 15223872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients
Number of subjects: 50
Study 15223872 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 10688810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs‐A1 (1 mg/kg/d)
Number of subjects: 59
Study 10688810 — intervention group
Group type: COMPARATOR
Intervention: Cs‐A3 (3 mg/kg/d)
Number of subjects: 59
Study 9093631 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (HF)
Number of subjects: 110
Study 9093631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (S-P)
Number of subjects: 110
Study 9093631 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 110
Study 1353088 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiseptics (alcohol wipes and hexachlorophane powder)
Number of subjects: 0
Study 1353088 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated with topical antiseptics)
Number of subjects: 0
Study 3922070 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 per cent lipid solution
Number of subjects: 0
Study 3922070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat solutions alone or in combination with isotonic concentrations of dextrose
Number of subjects: 0
Study 30659398 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative groin pain (P)
Number of subjects: 309
Study 30659398 — intervention group
Group type: COMPARATOR
Intervention: No preoperative pain (N)
Number of subjects: 309
Study 29465444 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 24
Study 29465444 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 28642552 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium chloride
Number of subjects: 120
Study 28642552 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine impregnated gauze
Number of subjects: 120
Study 26122686 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy + home exercise program
Number of subjects: 99